A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular AMD.
Phase of Trial: Phase IV
Latest Information Update: 12 May 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms DRAGON
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 04 May 2015 New trial record